16 hrs ago | Medical News
Positive results from study comparing exenatide once weekly to BYETTA
Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTAA injection taken twice daily, in patients with type 2 diabetes .
Finally Released From an Extended Review
It seems the Food and Drug Administration may have misread Eli Lilly 's New Drug Application.
Weekly Guru Bargains Highlights: CSTR, FICO, ALKS, AIG, DVR
Last weeka TMs top five guru bargain stocks were Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Group Inc, and Cal Dive International Inc.
Company and People Notes: PhRMA adds biopharm members; Dow spins off...
Company and People Notes: PhRMA adds biopharm members; Dow spins off expression technology; and more.
Public relations, press release distribution, investor relations, SEC filing
The event will take place from... LOS ANGELES-- --Universal Detection Technology , a developer of early-warning monitoring technologies to protect people from bioterrorism and other infe... MASHANTUCKET, Conn.-- --For the second consecutive year, the acclaimed Craftsteak restaurant at the MGM Grand at Foxwoods has received the coveted AAA-Four ...
News and FDA Updates for Access
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Alkermes Inks $10M Licensing Deal with Acceleron Pharma
Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion technology, which is designed to extend the circulating half-life of proteins and peptides.
Alkermes inks $10M licensing deal with Acceleron
Biotechnology concern Alkermes Inc. has invested $10 million for the licensing rights to a drug-development technology produced by Acceleron Pharma Inc.
4 Platform Drugmakers to Invest In
Platforms aren't just for acrobatic moves before splashing into the pool or '70s night at the disco.
Stocks on the move: Home Depot, MBIA, Playboy, Tween Brands
Shares of the following companies are having unusual moves in U.S. trading this morning.
Customer Interaction Solutions
Sign Up For Our Free Newsletter and Make Money!! MTCH,ALKS,ALTR,AMZN,ANSS,APOL
STOCK MARKETING INC PRESENTS : Matech Corp., Alkermes, Inc.,, Altera Corp., Amazon.com, Inc., ANSYS, Inc., Apollo Group, Inc.
Alkermes Initiates Phase 2 Clinical Study Of ALKS 33 For The Treatment Of Alcohol Dependence
Alkermes, Inc. announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders.
Alkermes moves alcohol dependency drug candidate to Phase 2 study
Alkermes Inc. has begun a Phase 2 clinical study of ALKS 33, the Cambridge biotech's drug candidate for treating alcohol dependence and other central nervous system disorders.
Tuesday's Big Gainers on Heavy Volume
Here is a list of stocks which traded higher Tuesday November 17, 2009 on unusually higher volume.
4-Star Stocks Poised to Pop: Alkermes
Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, small-cap biotech Alkermes has earned a respected four-star ranking .
Biotech Stocks: Alkermes gains; Cerus, InterMune tumble
Drug stocks dipped in early action Tuesday, while shares of Alkermes Inc. gained for the second day on positive news about two of its substance-abuse therapies.
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
On 11/16/09, Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.
Ivanhoe Mines Ltd., a Canada-based mining company, said Friday that its third-quarter loss narrowed as it recorded revenue and decreased its exploration expenses.
Bulls Buy Oshkosh, Alkermes: Options Recap
OptionMonster co-founder Pete Najarian provides options picks Monday, Wednesday and Friday in TheStreet.com's Deep in the Money Calls newsletter.
Alkermesa Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference
Alkermes, Inc. announced today that its corporate presentation will be webcast live by Lazard Capital Markets on Tuesday, November 17, 2009, at 3:10 p.m. ET from the St.
Also on Topix